Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, Catherine, Pilotte, Luc, Théate, Ivan, Stroobant, Vincent, Colau, Didier, Parmentier, Nicolas, Boon, Thierry, Van den Eynde, Benoît J·2003·Nature Medicine
DOI 10.1038/nm934

Cited by (1,003)

Items 501–600 of 1,003

  1. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance
    Renee B. Chang, Gregory Lawrence Beatty · 2020 · Journal of Leukocyte Biology
  2. Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
    Steve Robatel, Mirjam Schenk · 2022 · Cancers
  3. The Role of Dendritic Cells in Tissue-Specific Autoimmunity
    Jacques C. Mbongue, Dequina Nicholas, Anthony Francis Firek, William H. R. Langridge · 2014 · Journal of Immunology Research
  4. Cell‐autonomous control of interferon type I expression by indoleamine 2,3‐dioxygenase in regulatory CD19+ dendritic cells
    Anna Manlapat, David J. Kahler, Phillip Chandler, David H. Munn, Andrew L. Mellor · 2007 · European Journal of Immunology
  5. Inflammation‐induced activation of the indoleamine 2,3‐dioxygenase pathway: Relevance to cancer‐related fatigue
    Sangmi Kim, Brian J. Miller, Michael Edward Stefanek, Andrew H. Miller · 2015 · Cancer
  6. Signaling defects in anti‐tumor T cells
    Alan B. Frey, Ngozi R. Monu · 2008 · Immunological Reviews
  7. Targeting key dioxygenases in tryptophan–kynurenine metabolism for immunomodulation and cancer chemotherapy
    Christopher Austin, Louis M. Rendina · 2014 · Drug Discovery Today
  8. Inflammatory arthritis can be reined in by CpG-induced DC–NK cell cross talk
    Hsin-Jung Joyce Wu, Heloisa Sawaya, Bryce Anthony Binstadt, Margot Brickelmaier, Amanda L. Blasius, Leonid Gorelik, Umar Mahmood, Ralph Weissleder, John P. Carulli, Christophe O. Benoist et al. · 2007 · The Journal of Experimental Medicine
  9. In Vivo Uptake and Metabolism of α-[11C]Methyl- l -Tryptophan in Human Brain Tumors
    Csaba Juhász, Diane C. Chugani, Otto Muzik, Dafang Wu, Andrew Edward Sloan, Geoffrey R. Barger, Craig E. Watson, Aashit K. Shah, Sandeep Sood, Eser Lay Ergün et al. · 2005 · Journal of Cerebral Blood Flow & Metabolism
  10. Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes
    Feng‐Ying Huang, Jing Lei, Yan Sun, Fei Yan, Bin Chen, Liming Zhang, Zhuoxuan Lu, Rong Yue Cao, Yingying Lin, Cai-Chun Wang et al. · 2018 · OncoImmunology
  11. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
    Zhang, Xiaolong, Yang, Yuanyuan, Zhang, Leisheng, Lu, Yang, Zhang, Qing, Fan, Dongmei, Zhang, Yizhi, Zhang, Yanjun, Ye, Zhou, Xiong, Dongsheng · 2017 · Journal of Hematology & Oncology
  12. Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1
    Sanjeev Kumar, Jesse P. Waldo, Firoz Ali Jaipuri, Agnieszka Marcinowicz, Clarissa Van Allen, James Adams, Tanay Kesharwani, Xiaoxia Zhang, Richard A. Metz, Angela J. Oh et al. · 2019 · Journal of Medicinal Chemistry
  13. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
    Minah Kim, Petr Tomek · 2021 · Frontiers in Immunology
  14. The characterization and role of regulatory T cells in immune reactions
    Jacek, R. Wilczynski · 2007 · Frontiers in bioscience
  15. Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
    Theodore S. Johnson, David H. Munn · 2012 · Immunological Investigations
  16. Immunogenicity and immunomodulatory properties of HPMA-based polymers☆
    Blanka Řı́hová, Marek Kovář · 2009 · Advanced Drug Delivery Reviews
  17. Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
    Justin Paul Kline, Ian E. Brown, Yuan-Yuan Zha, Christian U. Blank, John H. Strickler, Harald Wouters, Long Zhang, Thomas Frank Gajewski · 2008 · Clinical Cancer Research
  18. The immunoregulatory role of IDO-producing human dendritic cells revisited
    Peter Terness, Jing-Jing Chuang, Gerhard Opelz · 2006 · Trends in Immunology
  19. Bariatric Surgery Cannot Prevent Tryptophan Depletion Due to Chronic Immune Activation in Morbidly Obese Patients
    Gerald Brandacher, Christiana Winkler, Franz Aigner, H. G. Schwelberger, K. Schroecksnadel, Raimund Margreiter, Dietmar Fuchs, Helmut G Weiss · 2006 · Obesity Surgery
  20. Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery
    Graça D. Almeida-Porada, Anthony Atala, Christopher D. Porada · 2020 · Molecular Therapy — Methods & Clinical Development
  21. Differential effects of the tryptophan metabolite3‐hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines
    William P. Weber, Chantal Feder‐Mengus, Alberto Chiarugi, Rachel Rosenthal, Anca Reschner, Reto Schumacher, Paul Zajac, Heidi Misteli, Daniel M. Frey, Daniel Oertli et al. · 2005 · European Journal of Immunology
  22. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression
    Adaobi E. Amobi, Feng Qian, Amit Anand Lugade, Kunle O. Odunsi · 2017 · Advances in experimental medicine and biology
  23. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
    Tony Avril, Stéphan Saïkali, Élodie Vauléon, Anne Jary, Abderrahmane Hamlat, Marie de Tayrac, Jean Mosser, Véronique Quillien · 2010 · Journal of Neuroimmunology
  24. Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers
    Paolo Puccetti, Francesca Fallarino, Antoîne Italiano, Isabelle Soubeyran, Gaëtan Marie MacGrogan, Marc Debled, Valérie Velasco, D. Bodet, Sandrine Eimer, Marc Veldhoen et al. · 2015 · PLoS ONE
  25. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy
    Elisabeth Naschberger, Roland S. Croner, Susanne Merkel, Arno W. Dimmler, Philipp Tripal, Kerstin Amann, Elisabeth Kremmer, Wolfgang Michael Brueckl, Thomas Papadopoulos, Christine Hohenadl et al. · 2008 · International Journal of Cancer
  26. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi, Masato Hoshi, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito et al. · 2010 · Annals of Hematology
  27. Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
    Mary B. Mockler, Melissa Jane Conroy, Joanne Lysaght · 2014 · Frontiers in Oncology
  28. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Ute F. Röhrig, A. Reynaud, Somi Reddy Majjigapu, Pierre Vogel, Florence Pojer, Vincent Zoete · 2019 · Journal of Medicinal Chemistry
  29. Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
    Yue Zheng, Yiran Yao, Tongxin Ge, Shengfang Ge, Renbing Jia, Xin Song, Ai Zhuang · 2023 · Journal of Experimental & Clinical Cancer Research
  30. Splicing of Distant Peptide Fragments Occurs in the Proteasome by Transpeptidation and Produces the Spliced Antigenic Peptide Derived from Fibroblast Growth Factor-5
    Alexandre Dalet, Nathalie Vigneron, Vincent Stroobant, Ken‐ichi Hanada, Benoit J. Van den Eynde · 2010 · The Journal of Immunology
  31. A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
    Meng‐Chi Yen, Chi‐Chen Lin, Yi‐Ling Chen, Shih-Shien Huang, Huei‐Jiun Yang, Chih‐Peng Chang, Huan-Yao Lei, Ming-Derg Lai · 2009 · Clinical Cancer Research
  32. 3-Hydroxykynurenine Suppresses CD4 + T-Cell Proliferation, Induces T-Regulatory-Cell Development, and Prolongs Corneal Allograft Survival
    Sarah S. Zaher, Conrad Germain, Hongmei Fu, Frank Larkin, Andrew J.T. George · 2011 · Investigative Ophthalmology & Visual Science
  33. Tumor stress, cell death and the ensuing immune response
    Evelyn Ullrich, Mathieu Bonmort, Grégoire Mignot, Guido Kroemer, Laurence Zitvogel · 2007 · Cell Death and Differentiation
  34. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
    Ben Creelan, Scott Joseph Antonia, Gerold Bepler, Timothy J. Garrett, George R. Simon, Hatem Hussein Soliman · 2013 · OncoImmunology
  35. 1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity
    Sophie Agaugué, Laure Perrin‐Cocon, Frédéric Coutant, Patrice André, Vincent Lotteau · 2006 · The Journal of Immunology
  36. Immunometabolism in cancer at a glance
    Katrin Singer, Wan-Chen Cheng, Marina P Kreutz, Ping‐Chih Ho, Peter J. Siska · 2018 · Disease Models & Mechanisms
  37. Local Expression of Indoleamine 2,3-Dioxygenase Protects Engraftment of Xenogeneic Skin Substitute
    Yunyuan Li, Edward E. Tredget, Abdi Ghaffari, Xiaoyue Lin, Ruhangiz Taghi Kilani, Aziz Ghahary · 2005 · Journal of Investigative Dermatology
  38. Studies on Tissue and Cellular Distribution of Indoleamine 2,3-Dioxygenase 2
    Masakazu Fukunaga, Yasuko Yamamoto, Misaki Kawasoe, Yuko Arioka, Yuki Murakami, Masato Hoshi, Kuniaki Saito · 2012 · Journal of Histochemistry & Cytochemistry
  39. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells
    Ascensión López, Estíbaliz Alegre, Joël LeMaoult, Edgardo Delfino Carosella, A GONZALEZ · 2006 · Molecular Immunology
  40. Novel Action of Indoleamine 2,3-Dioxygenase Attenuating Acute Lung Allograft Injury
    Hanzhong Liu, Li Liu, Bradley S. Fletcher, Gary A. Visner · 2005 · American Journal of Respiratory and Critical Care Medicine
  41. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
    Hélène Maby-El Hajjami, Patricia Amé-Thomas, Céline Pangault, Olivier Tribut, John De Vos, Rachel Jean, Nadège Bescher, Céline Monvoisin, Joëlle Dulong, Thierry Lamy et al. · 2009 · Cancer Research
  42. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    Jiaqi Huang, Alison M. Mondul, Stephanie J. Weinstein, Stella Koutros, Andriy Derkach, Edward D. Karoly, Joshua Neil Sampson, Steven C. Moore, Sonja I. Berndt, Demetrius Albanes · 2016 · British Journal of Cancer
  43. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
    Mitsuto Hanihara, Tomoyuki Kawataki, Kyoko Oh‐oka, Kentaro Mitsuka, Atsuhito Nakao, Hiroyuki Kinouchi · 2015 · Journal of neurosurgery
  44. Current status and perspectives in immunotherapy for metastatic melanoma
    Riccardo Marconcini, for the Italian Melanoma Intergroup (IMI), Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco De Rosa, Virginia Picasso, Lorenza Di Guardo, Carolina Cimminiello et al. · 2017 · Oncotarget
  45. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
    Bruno Gomes, Grégory Driessens, Derek W. Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin et al. · 2018 · Molecular Cancer Therapeutics
  46. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
    Geoffrey Thomas Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas Frank Gajewski, Bartosz Chmielowski, Brent Allen Hanks, Yufan Zhao, Robert Charles Newton et al. · 2019 · Journal for ImmunoTherapy of Cancer
  47. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
    Elisa Peranzoni, Vincenzo Ingangi, Elena Masetto, Laura Pinton, Ilaria Marigo · 2020 · Frontiers in Immunology
  48. Recent advances in clinical trials targeting the kynurenine pathway
    Ananda Staats Pires, Gayathri Sundaram, Benjamin Heng, Shivani Krishnamurthy, Bruce James Brew, Gilles J. Guillemin · 2021 · Pharmacology & Therapeutics
  49. Metabolic regulation of immunity in the tumor microenvironment
    Shen Li, Yu Zhang, Huan Tong, Haozhen Sun, Hu Liao, Qingfang Li, Xuelei Ma · 2025 · Cell Reports
  50. Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase
    Ciriana Orabona, Maria Teresa Pallotta, Ursula Grohmann · 2012 · Molecular Medicine
  51. Tryptophan degradation in patients with gynecological cancer correlates with immune activation
    Katharina Schroecksnadel, Christiana Winkler, Lothar Clemens Fuith, Dietmar Fuchs · 2004 · Cancer Letters
  52. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
    Ailin Li, Hampartsoum B. Barsoumian, Jonathan E. Schoenhals, Taylor R. Cushman, Mauricio S. Caetano, Xiaohong Wang, David R. Valdecanas, Sharareh Niknam, Ahmed I. A. Younes, Guang Li et al. · 2018 · Cancer Letters
  53. Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma
    Soudabeh Rad Pour, Hiromasa Morikawa, Narsis A. Kiani, Muyi Yang, Alireza Azimi, Gowhar Shafi, Ming-Mei Shang, Roland Baumgartner, Daniel F.J. Ketelhuth, Muhammad Anas Kamleh et al. · 2019 · Scientific Reports
  54. Harnessing the immune response to treat cancer
    Henry John Steer, Richard Lake, Anna K. Nowak, Bruce W.S. Robinson · 2010 · Oncogene
  55. Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
    Sonia Moretti, Elisa Menicali, Pasquale Voce, Silvia Morelli, Sara Cantarelli, Marialuisa Sponziello, Renato Colella, Francesca Fallarino, Ciriana Orabona, Alessia Alunno et al. · 2014 · The Journal of Clinical Endocrinology & Metabolism
  56. Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
    Xin Liu, R. Newton, Steven Friedman, Peggy Scherle · 2009 · Current Cancer Drug Targets
  57. Mycobacterium Leprae –Host-Cell Interactions and Genetic Determinants in Leprosy: an Overview
    Roberta Olmo Pinheiro, Jorgenilce de Souza Sales, Euzenir Nunes Sarno, Elizabeth Pereira Sampaio · 2011 · Future Microbiology
  58. Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella- Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors
    Edwin Ramos Manuel, Céline A. Blache, Rebecca Paquette, Teodora I. Kaltcheva, Hidenobu Ishizaki, Joshua D.I. Ellenhorn, Michael Hensel, Leonid S. Metelitsa, Don J. Diamond · 2011 · Cancer Research
  59. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment
    Kenneth A. Friedman, Alexander S. Brodsky, Shaolei Lu, Stephanie Wood, Anthony James Gill, Kara A. Lombardo, Dongfang Yang, Murray B. Resnick · 2016 · Modern Pathology
  60. Mesenchymal stem cells and cancer: Friends or enemies?
    Hong, In-Sun, Lee, Hwa-Yong, Kang, Kyung-Sun · 2014 · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
  61. Suppression of T-cell responses by tumor metabolites
    Katrin Singer, Eva Gottfried, Marina P Kreutz, Andréas Mackensen · 2011 · Cancer Immunology Immunotherapy
  62. Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography–Mass Spectrometry
    Lina Zhou, Lili Ding, Peiyuan Yin, Xin Lu, Xiaomei Wang, Junqi Niu, Pujun Gao, Guowang Xu · 2012 · Journal of Proteome Research
  63. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
    Alessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, Federica Loscocco, Giuseppe Visani, Sarah Parisi, Mariangela Lecciso, Darina Očadlíková, Lara Rossi, Elisa Gabucci et al. · 2014 · Expert Review of Hematology
  64. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications
    Elisabetta Cariani, Gabriele Missale · 2019 · Liver International
  65. Mechanisms of Immunosuppression in Colorectal Cancer
    Yang Zhang, Ashwani Rajput, Ning Yi Jin, Jing Wang · 2020 · Cancers
  66. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration and invasion of human hepatocellular carcinoma
    Haojie Jin, Yurong Zhang, Haiyan You, Xuemei Tao, Cun Wang, Guang‐Zhi Jin, Ning Wang, Haoyu Ruan, Dishui Gu, Xisong Huo et al. · 2015 · Scientific Reports
  67. Spontaneous Renal Allograft Acceptance Associated with “Regulatory” Dendritic Cells and IDO
    Charles H. Cook, Alice A. Bickerstaff, Jiao-Jing Wang, Tibor Nádasdy, Patricia Della Pelle, Robert B. Colvin, Charles G. Orosz · 2008 · The Journal of Immunology
  68. Epstein-Barr Virus Infection Induces Indoleamine 2,3-Dioxygenase Expression in Human Monocyte-Derived Macrophages through p38/Mitogen-Activated Protein Kinase and NF-κB Pathways: Impairment in T Cell Functions
    Wanli Liu, Yuehao Lin, Xiao Han, Shan Xing, Hao Chen, Peidong Chi, Ge Zhang · 2014 · Journal of Virology
  69. IL4I1: an inhibitor of the CD8+ antitumor T‐cell response in vivo
    Fanette Lasoudris, Céline Cousin, Armelle Prévost‐Blondel, Nadine Martin‐Garcia, Issam Abd‐Alsamad, Nicolás Ortonne, Jean‐Pierre Farcet, Flavia Castellano, Valérie Molinier‐Frenkel · 2011 · European Journal of Immunology
  70. Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
    Irina Banzola, Chantal Mengus, Stephen Frederic Wyler, Tvrko Hudolin, Gabriele Manzella, Alberto Chiarugi, Renzo Luciano Boldorini, Giovanni Sais, Tobias S. Schmidli, Gabriele Chiffi et al. · 2018 · Frontiers in Immunology
  71. Immunotherapy of Primary Brain Tumors: Facts and Hopes
    Robin Arthur Buerki, Zinal S. Chheda, Hideho Okada · 2018 · Clinical Cancer Research
  72. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy
    Lijie Zhai, Mahua Dey, Kristen L. Lauing, Galina Gritsina, Rajwant Kaur, Rimas Vincas Lukas, Martin Kelly Nicholas, ALFRED W. RADEMAKER, Carlos R. Dostal, Robert H. McCusker et al. · 2015 · Journal of Clinical Neuroscience
  73. The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells
    Sung Yong Lee, Hye Kyoung Choi, Kyung Ju Lee, Jin Yong Jung, Gyu Young Hur, Ki Hwan Jung, Je Hyeong Kim, Chol Shin, Jae Jeong Shim, Kwang Ho In et al. · 2008 · Journal of Immunotherapy
  74. Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon
    Karola Obojes, Oliver Andrés, Kwang Sik Kim, Walter Däubener, Jürgen Schneider‐Schaulies · 2005 · Journal of Virology
  75. Immunotherapeutic approaches to ovarian cancer treatment
    Cariad Chester, Oliver Dorigo, Jonathan S. Berek, Holbrook E K Kohrt · 2015 · Journal for ImmunoTherapy of Cancer
  76. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non–Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling
    Mingxiang Ye, Yong Zhang, Hongjun Gao, Yan Xu, Pengyu Jing, Jianxiong Wu, Xinxin Zhang, Jie Xiong, Chenfang Dong, Libo Yao et al. · 2017 · Clinical Cancer Research
  77. pH‐Sensitive Molecular‐Switch‐Containing Polymer Nanoparticle for Breast Cancer Therapy with Ferritinophagy‐Cascade Ferroptosis and Tumor Immune Activation
    Tiantian Zuo, Tianxu Fang, Jun Zhang, Jie Yang, Rui Xu, Zhihua Wang, Huizi Deng, Qi Shen · 2021 · Advanced Healthcare Materials
  78. A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer
    Niroshaathevi Arumuggam, Neil A. Bhowmick, H.P. Vasantha Rupasinghe · 2015 · Phytotherapy Research
  79. Fungal Dimorphism and Virulence: Molecular Mechanisms for Temperature Adaptation, Immune Evasion, and In Vivo Survival
    Gregory M. Gauthier · 2017 · Mediators of Inflammation
  80. B-Cell Depletion Promotes Aortic Infiltration of Immunosuppressive Cells and Is Protective of Experimental Aortic Aneurysm
    Basil W. Schaheen, Emily Downs, Vlad Serbulea, Camila Cruz Pereira Almenara, Michael D. Spinosa, Gang Su, Yunge Zhao, Prasad Srikakulapu, Cherié L. Butts, Coleen A. McNamara et al. · 2016 · Arteriosclerosis Thrombosis and Vascular Biology
  81. The Absence of IDO Upregulates Type I IFN Production, Resulting in Suppression of Viral Replication in the Retrovirus-Infected Mouse
    Masato Hoshi, Kuniaki Saito, Akira Hara, Ayako Taguchi, Hirofumi Ohtaki, Ryo Tanaka, Hidetsugu Fujigaki, Yosuke Osawa, Masao Takemura, Hidetoshi Matsunami et al. · 2010 · The Journal of Immunology
  82. Sleeping Beauty‐based gene therapy with indoleamine 2,3‐dioxygenase inhibits lung allograft fibrosis
    Hanzhong Liu, Li Liu, Bradley S. Fletcher, Gary A. Visner · 2006 · The FASEB Journal
  83. Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies
    Csaba Juhász, Zeina A. Nahleh, Ian M. Zitron, Diane C. Chugani, Majid Janabi, Subhayu Bandyopadhyay, Rouba Ali‐Fehmi, Thomas J. Mangner, Pulak K. Chakraborty, Sandeep Mittal et al. · 2012 · Nuclear Medicine and Biology
  84. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion
    Sun‐Mi Lee, Young-Suk Lee, Jae-Hyeog Choi, Sae-Gwang Park, Il‐Whan Choi, Young‐Don Joo, Won-Sik Lee, Jeong-Nyeo Lee, Inhak Choi, Su‐Kil Seo · 2010 · Immunology Letters
  85. Plectosphaeroic Acids A, B, and C, Indoleamine 2,3-Dioxygenase Inhibitors Produced in Culture by a Marine Isolate of the Fungus Plectosphaerella cucumerina
    Gavin Carr, Wendy Tay, Helen Bottriell, Sarah Kristin Andersen, A. Grant Mauk, Raymond J. Andersen · 2009 · Organic Letters
  86. Synthesis of Indoleamine 2,3-Dioxygenase Inhibitory Analogues of the Sponge Alkaloid Exiguamine A
    Gavin Carr, Marco K. W. Chung, A. Grant Mauk, Raymond J. Andersen · 2008 · Journal of Medicinal Chemistry
  87. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
    Kunle O. Odunsi, Feng Qian, Amit Anand Lugade, Han Yu, Melissa Ann Geller, Steven P. Fling, Judith C. Kaiser, Andreanne M. Lacroix, Leonard D’Amico, Nirasha Ramchurren et al. · 2022 · Science Translational Medicine
  88. Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?
    Jérry Y. Niederkorn · 2012 · Frontiers in Immunology
  89. TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
    André Kunert, Trudy Straetemans, Coen Govers, Cor Lamers, Ron H.J. Mathijssen, Stefan Sleijfer, Reno Debets · 2013 · Frontiers in Immunology
  90. The Importance of NAD in Multiple Sclerosis
    William Todd Penberthy, Ikuo Tsunoda · 2009 · Current Pharmaceutical Design
  91. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression
    Marion Wobser, Heike Voigt, Roland Houben, Andreas O. Eggert, Matthias Freiwald, Ulrike Kaemmerer, Eckhart Kaempgen, David Schrama, Juergen C. Becker · 2006 · Cancer Immunology Immunotherapy
  92. Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node Metastasis
    Jinpu Yu, Jingyan Sun, Shizhen Emily Wang, Hui Li, Shui Cao, Yizi Cong, Juntian Liu, Xiubao Ren · 2011 · Clinical and Developmental Immunology
  93. Interactions of Tomato and Botrytis cinerea Genetic Diversity: Parsing the Contributions of Host Differentiation, Domestication, and Pathogen Variation
    Nicole E. Soltis, Susanna Atwell, Gongjun Shi, Rachel F. Fordyce, Raoni Gwinner, Dihan Gao, Aysha Shafi, Daniel J. Kliebenstein · 2019 · The Plant Cell
  94. Cancer immunotherapy
    Thomas F. Gajewski · 2012 · Molecular Oncology
  95. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
    Ombretta Melaiu, Valeria Lucarini, Roberto Giovannoni, Doriana Fruci, Federica Gemignani · 2020 · Seminars in Cancer Biology
  96. The Immune System in the Pathogenesis of Ovarian Cancer
    Bridget Charbonneau, Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, Melissa S. DeRycke · 2013 · Critical Reviews in Immunology
  97. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
    Ana Paula Duarte de Souza, Cristina Bonorino · 2009 · Expert Review of Anticancer Therapy
  98. Synovial Autoreactive T Cells in Rheumatoid Arthritis Resist IDO-Mediated Inhibition
    Lingqiao Zhu, Fang Ji, Yuan Wang, Yi Zhang, Qiang Liu, Jingwu Z. Zhang, Kouji Matsushima, Qi Cao, Yi Zhang · 2006 · The Journal of Immunology
  99. Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy
    Shu‐Yu Lin, Teng‐Kuang Yeh, Ching‐Chuan Kuo, Jen‐Shin Song, Ming-Fu Cheng, Fang-Yu Liao, Min‐Wu Chao, Han-Li Huang, Yi-Lin Chen, Chun-Yu Yang et al. · 2015 · Journal of Medicinal Chemistry
  100. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
    Iva Truxová, David Cibula, Radek Špíšek, Jitka Palich Fucikova · 2023 · Journal for ImmunoTherapy of Cancer